WO1995032958A1 - Novel substituted benzimidazoles - Google Patents
Novel substituted benzimidazoles Download PDFInfo
- Publication number
- WO1995032958A1 WO1995032958A1 PCT/SE1995/000518 SE9500518W WO9532958A1 WO 1995032958 A1 WO1995032958 A1 WO 1995032958A1 SE 9500518 W SE9500518 W SE 9500518W WO 9532958 A1 WO9532958 A1 WO 9532958A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluoro
- methyl
- sulfinyl
- benzimidazole
- cyclopropylmethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention provides such compounds, which are novel salts of single enantiomers of 5-fluoro-2-[[(4-cyclopropylmethoxy-2- pyridinyl)methyl]sulfinyl]-lH-ber-zimidazole as well as the novel single enantiomers of the neutral form of said compound.
- novel compounds of the invention could be expected to undergo racemization in neutral pH as well as in basic pH. See for example Brandstr ⁇ m et al. Acta Chemica Scandinavica 43 (1989) p. 536-547.
- the inventors now found that the novel single enantiomers of 5-fluoro-2-[[(4- cyclopropybnethoxy-2-pyridinyl)me yl]sulfmyl]-lH-benzimidazole as well as its therapeutically acceptable salts are stable towards racemization.
- the present invention refers to the new single enantiomers of 5-fluoro-2-[[(4- cyclopropyl-methoxy-2-pyridmyl)memyl]sulfmyl]-lH-ber ⁇ irnidazole according to compounds la and lb la (+)-enantiomer lb (-)-enantiomer
- Such salts are for example the Na + , Mg2+, Ca2+, Li + , K + and N + (R)4 salts of the single enantiomers of said compound, where R is an alkyl group with 1-4 carbon atoms, i.e.
- Particularly preferred salts of the compound of the invention are the Na + , Mg2+ and Ca2+ salts of the single enantiomers of 5-fluoro-2-[[(4-cyclopropylmethoxy-2- pyridmyl)methyl]sulfinyl]-lH-benzimidazole.
- optically pure compound of the invention is meant the (+)- enantiomer of said compound essentially free from the corresponding (-)- enantiomer and the (-)-enantiomer essentially free from the corresponding (+)- enantiomer, respectively.
- every single compound of the invention is obtained in high optical purity.
- the compounds of the invention are easy to obtain.
- the novel optically pure compounds are stable towards racemization in neutral pH as well as basic pH.
- the single enantiomeric compounds of the invention as well as the racemate show exceedingly high bioavailability, and still said compounds are very effective as inhibitors of gastric acid secretion and exhibit a high chemical stability in solution at a neutral pH.
- the compounds according to the invention may be used for inhibiting gastric acid secretion in mammals and man.
- the single enantiomeric compounds of the invention may be used for the treatment of gastric acid-related diseases and gastrointestinal inflammatory diseases in mammals and man, such as gastric ulcer, duodenal ulcer, reflux esophagi tis, and gastritis.
- the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable e.g. in patients on NSAID therapy, in patients with gastrinomas, and in patients with accute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre- and postoperatively to prevent acid aspiration and stress ulceration.
- the compound of the invention may also be used for treatment or prophylaxis of inflammatory conditions in mammals, including man, especially those involving lysozymal enzymes. Conditions that may be specifically mentioned are rheumatoid arthritis and gout.
- the compound of the invention may be also useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections.
- a further aspect of the invention is the diasteromeric mixture of a regioisomeric mixture having the formula IV, which is an intermediate used in the specific method of preparation, wherein the fluoro substituent in the benzimidazole moiety is in position 5 or 6.
- optically pure compounds of the invention i.e. the single enantiomers
- the optically pure compounds of the invention are prepared by separating the stereoisomers of a diastereomeric mixture of the regioisomeric mixture of the following type, 5- and 6-fluoro-2-[[(4- cyclopropylmethoxy-2-pyridinyl)methyl]-(R/S)-sulfinyl]-l-[(R)-acyloxymethyl]- lH-benzimidazole, formula V
- the diastereomeric esters can be separated either by chromatography or fractional crystallization.
- T e solvolysis usually takes place together with a base in a protic solvent such as alcohols or water; or with a base in a mixture of acetonitrile and water, but the acyl group may also be hydrolysed off by a base in an aprotic solvent such as dimethylsulfoxide or dimethylformamide.
- the reacting base may be OH" or R ⁇ O" where R ⁇ can be any alkyl or aryl group.
- the resulting compound in neutral form is treated with a base, such as NaOH, in an aqueous or nonaqueous medium, or with NaOR ⁇ wherein R ⁇ is an alkyl group containing 1-4 carbon atoms, or with NaNH2- Also alkaline salts wherein the cation is Li + or K + may be prepared using lithium or potassium salts of the above mentioned bases.
- a base such as NaOH
- NaOR ⁇ wherein R ⁇ is an alkyl group containing 1-4 carbon atoms
- alkaline salts wherein the cation is Li + or K + may be prepared using lithium or potassium salts of the above mentioned bases.
- the crystalline form of the single enantiomers of the Na + salt may also be prepared by adding NaOH to a mixture of the single enantiomeric compound of invention in neutral form and a non-aqueous medium, such as a mixture of 2- butanone and toluene.
- the optically pure compound of the invention in the neutral form is treated with a base, such as Mg(OR3)2, wherein R ⁇ is an alkyl group containing 1-4 carbon atoms, in a non- aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran.
- a base such as Mg(OR3)2 wherein R ⁇ is an alkyl group containing 1-4 carbon atoms
- a non- aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran.
- the optically pure Mg 2+ salts may also be prepared by treating single enantiomeric compound of the invention as a sodium salt with an aqueous solution of an inorganic magnesium salt such as MgCl2, whereupon the Mg2+ salts are precipitated.
- the single enantiomers, i.e. the optically pure compounds, of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other modes of administrations.
- the pharmaceutical formulations contain the single enantiomers of the invention normally in combination with a pharmaceutically acceptable carrier.
- the carrier may be in form of a solid, semi- solid or liquid diluent, or capsule.
- These pharmaceutical preparations are a further object of the invention.
- the amount of active compound is between 0.1- 95% by weight of the preparation, between 0.2-20% by weight in preparations for parenteral use and between 1-50% by weight in preparations for oral administration.
- An active compound in a form with high solubility in water is requested for a parenteral preparation, for some oral preparations an active compound in a form with low solubility is suitable.
- the pure enantiomeric compound may be mixed with a solid, powdered carrier, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier, stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylenglycol waxes.
- a solid, powdered carrier such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier
- stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium
- Granules and tablets may be coated with an enteric coating which protects the active compound from acid catalysed degradation as long as the dosage form remains in the stomach.
- the enteric coating is chosen among pharmaceutically acceptable enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers and the like, if preferred in combination with a suitable plasticizer. To the coating various dyes may be added in order to distinguish among tablets or granules with different amounts of the active compound present.
- Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Soft gelatine capsules may also be enteric-coated as described above.
- Methylene chloride 2000 g I Compound according to Example 7, powder was mixed with lactose and granulated with a water solution of methyl cellulose and sodium carbonate. The wet mass was forced through a sieve and the granulate dried in an oven. After drying the granulate was mixed with polyvinylpyrrolidone and magnesium stearate. The dry mixture was pressed into tablet cores (10 000 tablets), each tablet containing 50 mg of active substance, in a tabletting machine using 7 mm diameter punches.
- a parenteral formulation for intravenous use containing 4 mg of active compound per ml, was prepared from the following ingredients:
- the active compound was dissolved in water to a final volume of 1000 ml.
- the solution was filtered through a 0.22 urn filter and immediately dispensed into 10 ml sterile ampoules. The ampoules were sealed.
- Suppositories were prepared from the following ingredients using a welding procedure. Each suppository contained 40 mg of active compound.
- the active compound was homogenously mixed with Witepsol H-15 at a temperature of 41° C.
- the molten mass was volume filled into pre-fabricated suppository packages to a net weight of 1.84 g. After cooling the packages were heat sealed.
- Each suppository contained 40 mg of active compound.
- the stability of the optically pure compounds of the invention towards racemization has been measured at low concentrations (10 " 5 M) at 37°C in aqueous buffer solutions at pH 7 and pH 11.
- the stereo chemical stability was measured by comparing the optical purity for the (+)-isomer of 5-fluoro-2-[[(4- c clopropyln ⁇ ethoxy-2-pyridmyl)memyl]sulfmyl]-lH-benzirmdazo in buffer solution immediately after dissolving and after several hours.
- the surprising high stereo chemical stability in neutral as well as in alkaline conditions for the compounds of invention is exemplified by the fact that no racemization for the test compound was obtained neither at pH 7 nor at pH 11, even after 28 hours. At pH 7, however, the chemical degradation of the compounds are much apparent after 28 hours.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26329/95A AU2632995A (en) | 1994-05-27 | 1995-05-11 | Novel substituted benzimidazoles |
EP95921186A EP0712400A1 (en) | 1994-05-27 | 1995-05-11 | Novel substituted benzimidazoles |
CA002166987A CA2166987A1 (en) | 1994-05-27 | 1995-05-11 | Novel substituted benzimidazoles |
JP8500729A JPH09504556A (en) | 1994-05-27 | 1995-05-11 | New substituted benzimidazoles |
BR9506234A BR9506234A (en) | 1994-05-27 | 1995-05-11 | Unique enanciomeric compounds use the same processes to prepare the same and sodium salt of (+) - and (-) - 5-fluor-2 - (((4-cyclopropylmethoxy-2 -prinidinyl) meti) sulfinyl-1h-benzimidazole in its crystalline forms for the treatment of inflammatory gastrointestinal diseases and pharmaceutical preparation |
EE9600010A EE9600010A (en) | 1994-05-27 | 1995-05-11 | Novel substituted benzimidazoles |
IS4320A IS4320A (en) | 1994-05-27 | 1996-01-17 | New substituted benzimidazole |
NO960267A NO960267D0 (en) | 1994-05-27 | 1996-01-23 | Newly substituted benzimidazoles |
FI960366A FI960366A (en) | 1994-05-27 | 1996-01-26 | New substituted benzimidazoles |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25616894A | 1994-05-27 | 1994-05-27 | |
ATPCT/SE94/00510 | 1994-05-27 | ||
SE9400510 | 1994-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995032958A1 true WO1995032958A1 (en) | 1995-12-07 |
Family
ID=20392943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1995/000518 WO1995032958A1 (en) | 1994-05-27 | 1995-05-11 | Novel substituted benzimidazoles |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0712400A1 (en) |
JP (1) | JPH09504556A (en) |
CN (1) | CN1128998A (en) |
AU (1) | AU2632995A (en) |
BR (1) | BR9506234A (en) |
CA (1) | CA2166987A1 (en) |
CZ (1) | CZ21896A3 (en) |
EE (1) | EE9600010A (en) |
FI (1) | FI960366A (en) |
IL (1) | IL113603A0 (en) |
IS (1) | IS4320A (en) |
MA (1) | MA23562A1 (en) |
PL (1) | PL312691A1 (en) |
TN (1) | TNSN95063A1 (en) |
WO (1) | WO1995032958A1 (en) |
ZA (1) | ZA954129B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0795024B1 (en) * | 1994-11-28 | 2003-02-19 | AstraZeneca AB | Enantioselective preparation of pharmaceutically active sulfoxides by biooxidation |
EP0795025B1 (en) * | 1994-11-28 | 2003-04-23 | AstraZeneca AB | Enantioselective preparation of pharmaceutically active sulfoxides by bioreduction |
USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008278A (en) * | 1988-12-22 | 1991-04-16 | Aktiebolaget Hassle | Therapeutically active compound and a process for its preparation |
DE4035455A1 (en) * | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | ENANTIOMER SEPARATION |
-
1994
- 1994-05-29 TN TNTNSN95063A patent/TNSN95063A1/en unknown
-
1995
- 1995-05-03 IL IL11360395A patent/IL113603A0/en unknown
- 1995-05-11 BR BR9506234A patent/BR9506234A/en not_active Application Discontinuation
- 1995-05-11 CN CN95190483A patent/CN1128998A/en active Pending
- 1995-05-11 WO PCT/SE1995/000518 patent/WO1995032958A1/en not_active Application Discontinuation
- 1995-05-11 AU AU26329/95A patent/AU2632995A/en not_active Abandoned
- 1995-05-11 EP EP95921186A patent/EP0712400A1/en not_active Withdrawn
- 1995-05-11 PL PL95312691A patent/PL312691A1/en unknown
- 1995-05-11 CZ CZ96218A patent/CZ21896A3/en unknown
- 1995-05-11 CA CA002166987A patent/CA2166987A1/en not_active Abandoned
- 1995-05-11 JP JP8500729A patent/JPH09504556A/en active Pending
- 1995-05-11 EE EE9600010A patent/EE9600010A/en unknown
- 1995-05-19 ZA ZA954129A patent/ZA954129B/en unknown
- 1995-05-26 MA MA23900A patent/MA23562A1/en unknown
-
1996
- 1996-01-17 IS IS4320A patent/IS4320A/en unknown
- 1996-01-26 FI FI960366A patent/FI960366A/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008278A (en) * | 1988-12-22 | 1991-04-16 | Aktiebolaget Hassle | Therapeutically active compound and a process for its preparation |
DE4035455A1 (en) * | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | ENANTIOMER SEPARATION |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0795024B1 (en) * | 1994-11-28 | 2003-02-19 | AstraZeneca AB | Enantioselective preparation of pharmaceutically active sulfoxides by biooxidation |
EP0795025B1 (en) * | 1994-11-28 | 2003-04-23 | AstraZeneca AB | Enantioselective preparation of pharmaceutically active sulfoxides by bioreduction |
USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
Also Published As
Publication number | Publication date |
---|---|
TNSN95063A1 (en) | 1996-02-06 |
JPH09504556A (en) | 1997-05-06 |
BR9506234A (en) | 1997-08-12 |
MA23562A1 (en) | 1995-12-31 |
CN1128998A (en) | 1996-08-14 |
IS4320A (en) | 1996-01-17 |
IL113603A0 (en) | 1995-08-31 |
AU2632995A (en) | 1995-12-21 |
PL312691A1 (en) | 1996-05-13 |
EE9600010A (en) | 1996-04-15 |
FI960366A0 (en) | 1996-01-26 |
CA2166987A1 (en) | 1995-12-07 |
FI960366A (en) | 1996-01-26 |
EP0712400A1 (en) | 1996-05-22 |
ZA954129B (en) | 1995-11-27 |
CZ21896A3 (en) | 1996-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2139653C (en) | Optically pure salts of pyridinylmethyl sulfinyl-ih- benzimidazole compounds | |
US6875872B1 (en) | Compounds | |
WO1995032957A1 (en) | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles | |
AU2633095A (en) | Novel dialkoxy-pyridinyl-benzimidazole derivatives | |
EP0712400A1 (en) | Novel substituted benzimidazoles | |
AU676337C (en) | Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds | |
SK5896A3 (en) | Substituted benzimideazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95190483.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995921186 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2166987 Country of ref document: CA Ref document number: 287577 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5896 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-218 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 960366 Country of ref document: FI |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995921186 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-218 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995921186 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV1996-218 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |